Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Target Price at $44.60

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received a consensus rating of “Hold” from the eight ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $44.60.

BLUE has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of bluebird bio in a research note on Monday. They issued a “sell” rating on the stock. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Barclays decreased their target price on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. Finally, Wells Fargo & Company cut their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th.

Institutional Trading of bluebird bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. bought a new stake in shares of bluebird bio in the 4th quarter worth approximately $175,000. State Street Corp boosted its holdings in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares in the last quarter. Geode Capital Management LLC increased its position in bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares during the period. Finally, Barclays PLC raised its holdings in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Trading Up 1.7 %

Shares of BLUE opened at $4.16 on Tuesday. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60. The stock has a market cap of $40.73 million, a PE ratio of -0.11 and a beta of 0.41. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The business’s 50-day moving average price is $4.41 and its 200-day moving average price is $6.96.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.